about
A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS)The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathwayProfiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.Human Blood Autoantibodies in the Detection of Colorectal Cancer.KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancerThe role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs.Clinical utility of reverse phase protein array for molecular classification of breast cancer.Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.A signalome screening approach in the autoinflammatory disease TNF Receptor Associated Periodic Syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome.Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer.The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.SUMOylation proteins in breast cancer.Development and validation of protein microarray technology for simultaneous inflammatory mediator detection in human sera.Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection.Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.Ex vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome.SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cellsClinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.Utility, reliability and reproducibility of immunoassay multiplex kits.Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction.The mannose receptor negatively modulates the Toll-like receptor 4-aryl hydrocarbon receptor-indoleamine 2,3-dioxygenase axis in dendritic cells affecting T helper cell polarization.Autoantibodies of IgM and IgG classes show differences in recognition of multiple autoantigens in chronic obstructive pulmonary disease.The application of protein microarray assays in psychoneuroimmunology.Characterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885.Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.The intracellular signalling pathway signature (the signalome) in PBMCs in the presence of a common TRAPS-associated genetic variant, TNFRSF1A p.(Arg121Gln) (legacy p.R92Q) is distinct from normal PBMCs and from other pathogenic variants.A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile InfectionPatients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulationTobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells
P50
Q34851612-BBE82D30-8EE7-40F8-A987-C0791FFF89A2Q35559391-20ABB076-0A51-4CC3-A9E8-E3321CB28BE0Q35998772-9F40FB38-5B66-456B-A619-0059F1896004Q36068902-BC85DAC6-9B7A-4E84-AE81-30E89EB251C0Q36086823-17C8EFEC-B17D-4F88-8D77-B1A3FC897BADQ37678976-2289293E-756D-4EFD-99BA-0B288C53D9E3Q38383140-FBE7B532-2054-4B6C-83F6-15B42EA91AE2Q38391935-6341F979-297B-4566-A547-11236CEE3609Q38599275-E014ED32-E6EE-4CB6-8879-E7314A8C00C0Q38755888-C2D4A1C9-548B-4F34-B3EF-9B796A20670EQ38850188-224F5C2F-1873-407D-B25B-3957B69CE442Q38900933-3C1061BB-8392-4943-A2BA-DF5B968A5F2BQ38907680-C05F05B9-98A6-4ADE-8330-46B28A916579Q39019431-D56B9B36-B183-4B26-A7AC-1A57CF91F45CQ39100710-A860BC5F-509C-4CD9-822E-1252B21EF993Q39159264-8AA26EED-3C31-470B-ACE1-587540870453Q39974818-35369C0F-D8E0-40D1-8238-AA35BEB65B2AQ40110456-45169B17-C688-444C-9B9F-CA62B2143A8BQ41081937-E2EEF0C7-EC0C-4FF7-B7AD-1A7CA89BFD4AQ41131357-A812A369-6574-4E7C-B662-2E79A4FD7F70Q41959768-7B9DAD1A-5B0A-4402-B9CC-A27D0146DDD1Q42496885-E51B5039-3731-4E75-9B98-E1B60A01F1BDQ44454992-601B6AB1-CB3A-4FED-AF7B-2933D8E5AF29Q46179551-131D5786-16C1-4D76-919E-9E93AE6D5B83Q46372193-6698A76D-2584-4217-9E54-2D3A4390DC8FQ47739362-493DA4A9-4962-4DB2-ADD2-6B7671F1F053Q48507369-DA3FEDC4-034B-4AAD-8E8E-067DCB521B0EQ50052167-FD24B7F2-65ED-402D-9BD2-31D06BFB04C9Q50437809-E3830813-D133-431C-90F5-BC0FBB53FA5AQ50489396-E6D741A6-7E8B-417C-A1DB-C4DD39081C0AQ54878412-D33FEB19-6EA4-4BDE-B49B-048FF6C9EB58Q89472132-AF6F8050-D4C5-47C7-A225-CF4DFA11810FQ90140104-7337B180-12B5-4E1E-929B-11791BFF5D1FQ91509552-4B933301-246E-41E5-AEC7-8FED249A145B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ola H Negm
@ast
Ola H Negm
@en
Ola H Negm
@es
Ola H Negm
@nl
type
label
Ola H Negm
@ast
Ola H Negm
@en
Ola H Negm
@es
Ola H Negm
@nl
prefLabel
Ola H Negm
@ast
Ola H Negm
@en
Ola H Negm
@es
Ola H Negm
@nl
P106
P31
P496
0000-0002-5999-6012